Online Course
on demand
20
May
2022
21
May
2022
Precision Testing Early and Later: a Tool for Diagnosis and Better Treatment?
BACKGROUND
The complexities of solid tumours are now evident for all. A better understanding of determinants of tumour behaviour and response to treatment is gained every day, and the term “precision testing” is often used. In 2021 SPCC conducted a series of webinars and is continuing to work on this topic.
 
Knowledge of the tests needed and their potential role in guiding treatment choices are important topics, as are accessibility and reimbursement of these tests. From treatment target evaluation to molecular oncology and advanced genomics, precision testing is aimed at ensuring that the right treatment is administered to the right patient at the right time, leading to a better outcome. Some tests may play a role in early detection and help to avoid unnecessary treatment and reduce costs.  The most unacceptable cost is the use of ineffective therapy. From the healthcare system perspective, precision testing brings more certainty on treatment outcomes and improves the sustainability and efficiency of healthcare. From the patient perspective, precision testing makes it possible to find the best available treatments and improves outcomes and quality of life.
 
However, due to regulatory, access and reimbursement barriers, even well-proven precision testing is not offered to all patients in Europe, not to speak of on global level. There is also a lack of the infrastructure needed to support and take advantage of genomic and molecular testing, including the development of networks to discuss the implications of the results in specific tumour boards. Even in countries where the infrastructure does exist, health care providers need more adequate information, knowledge and awareness, and patients require education and empowerment in order to ensure proper molecular characterisation of every patient’s tumour.
 
 
COURSE GOALS
The course programme will lead to a better understanding of:
- potential of precision testing techniques
- limits of use of these technique
- regulatory issues 
 
 
TARGET GROUP
Oncologists – Pathologists - HCPs - Patients’ Representatives - Professionals working in Cancer Institutes - Healthcare Public Authorities
 
 
COURSE FORMAT
The course will be held online with the participation of world-renowned experts, some of them already involved in the 2021 SPCC Precision Testing webinars.
It will be free of charge and can be accessed by registering on SPCC's OncoCorner e-learning platform.
The material will remain available on-demand.
 
 
COURSE CONTENT
The event will consist of 2 consecutive days of live sessions with recorded and live contributions.
 
 
CME ACCREDITATION AND CERTIFICATES
Application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 4 CME credits have been granted to this event.
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.
 
 
REGISTRATION
Event attendance is free of charge.

 
ACKNOWLEDGEMENTS 
Sharing Progress in Cancer Care wishes to express its appreciation to Bayer and Lilly for their unrestricted funding support and unrestricted educational grant.
20/05/2022 14:30 CEST

Early diagnosis: hope and reality

20/05/2022 14:30 CEST

Welcome and Introduction

Chair: Anna Batistatou, GR
Chair: Marzia Zambon, IT
20/05/2022 14:40 CEST

Updates on early detection of treatment intervention targets in all cancers from the pathologist's perspective

Expert: Holger Moch, CH
20/05/2022 15:00 CEST

Reality and limitations of multicancer early diagnosis blood tests

Expert: Allan Hackshaw, UK
20/05/2022 15:20 CEST

Precision Genomic Testing: Primed for Prime Time

Expert: Mark Lawler, UK
20/05/2022 15:40 CEST

Accessibility to precision testing: barriers that need to be overcome

Expert: Milo Frattini, CH
20/05/2022 16:00 CEST

Q&A and Live Discussion

Chair: Anna Batistatou, GR
Chair: Marzia Zambon, IT
Expert: Milo Frattini, CH
Expert: Allan Hackshaw, UK
Expert: Mark Lawler, UK
Expert: Holger Moch, CH
20/05/2022 16:25 CEST

Closing Remarks

Chair: Anna Batistatou, GR
Chair: Marzia Zambon, IT
21/05/2022 11:00 CEST

Applying modern technology: when is it proven useful?

21/05/2022 11:00 CEST

Welcome and Introduction

Chair: Anna Batistatou, GR
Chair: Marzia Zambon, IT
21/05/2022 11:10 CEST

Realising the potential of precision healthcare

Expert: Alastair Burt, UK
21/05/2022 11:30 CEST

Precision diagnostics for non-small cell lung cancer: what to ask for

Expert: Jordi Remon-Masip, FR
21/05/2022 11:50 CEST

Current developments in mCRC: 1) Continuum of care strategy; 2) Biomarker based precision medicine in pre-treated patients

Expert: Eric Van Cutsem, BE
21/05/2022 12:10 CEST

My patient’s ER+ HER2- tumour escapes first-line breast cancer treatment: which testing helps me find an active therapy?

Expert: Nadia Harbeck, DE
21/05/2022 12:30 CEST

Q&A and Live Discussion

Chair: Anna Batistatou, GR
Chair: Marzia Zambon, IT
Expert: Anne-Marie Baird, CH
Expert: Alastair Burt, UK
Expert: Nadia Harbeck, DE
Expert: Jordi Remon-Masip, FR
Expert: Eric Van Cutsem, BE
21/05/2022 12:55 CEST

Closing Remarks

Chair: Anna Batistatou, GR
Chair: Marzia Zambon, IT
Anne-Marie Baird

LuCE Lung Cancer Europe, Bern, Switzerland
Anna Batistatou

University of Ioannina, Ioannina, Greece
Alastair Burt

University of Adelaide, AU and Newcastle University, Newcastle, United Kingdom
Milo Frattini

Institute of Pathology, Cantonal Hospital, Locarno, Switzerland
Allan Hackshaw

Cancer Research UK & UCL Cancer Trials Centre, University College London, London, United Kingdom
Nadia Harbeck

Breast Center, LMU University Hospital, Munich, Germany
Mark Lawler

European Cancer Organisation and Queen's University Belfast, Belfast, United Kingdom
Holger Moch

European Society of Pathology and University Hospital Zurich, Zurich, Switzerland
Jordi Remon-Masip

Institut Gustave Roussy, Villejuif, France
Eric Van Cutsem

University of Leuven, Leuven, Belgium
Marzia Zambon

EUROPA DONNA - The European Breast Cancer Coalition, Milan, Italy
Login for the Online Course

Under the auspices of

ECPC - European Cancer Patient Coalition

EUROPA DONNA

European Society of Pathology